Cécile Pautas

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré et al. · The Lancet · 2012 · 975 citations

Hematological Malignancy, Oncology, Gemtuzumab Ozogamicin +8

Empirical versus Preemptive Antifungal Therapy for High‐Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial

Catherine Cordonnier, Cécile Pautas, Sébastien Maury et al. · Clinical Infectious Diseases · 2009 · 385 citations

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Éric Jourdan, Nicolas Boissel, Sylvie Chevret et al. · Blood · 2013 · 350 citations

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré et al. · Haematologica · 2018 · 336 citations · Full text

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux et al. · Leukemia · 2006 · 282 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10